Campaign Description
Public Health & HIV Prevention Campaign
By Rouen Foundation
$250,000 Funding Goal
Campaign Location: Nigeria, Africa
Campaign Focus: HIV prevention, adolescent health, medical access, education and community outreach
Proposed Duration: 12 Months
Funding Goal: $250,000 USD
1. Campaign Overview
Every young person deserves the opportunity to grow up healthy, protected and free from preventable HIV infection.
Across Nigeria, HIV remains an important public health challenge. Adolescents and young people, particularly adolescent girls and young women and other populations facing increased HIV exposure, need better access to reliable prevention information, confidential healthcare and evidence-based medical services.
We are launching the Protect Nigeria's Next Generation from HIV campaign to help expand access to HIV prevention services, including long-acting injectable lenacapavir (LEN), where medically appropriate and available through authorized healthcare providers.
Lenacapavir is an innovative HIV pre-exposure prophylaxis (PrEP) medicine administered twice yearly. It offers an additional prevention option for HIV-negative people who may benefit from PrEP, especially those who face difficulties taking daily preventive medication.
The World Health Organization recommended twice-yearly injectable lenacapavir as an additional HIV prevention option in July 2025. Nigeria subsequently introduced this prevention option nationally in March 2026.
World Health Organization+1
Through this campaign, we aim to support community awareness, voluntary HIV testing, qualified medical consultations, access to approved prevention services, healthcare worker training and follow-up support.
Our mission is simple: Help protect young lives through education, prevention and equitable access to healthcare.
2. Why This Campaign Matters
Nigeria continues to face a substantial HIV burden.
According to UNAIDS country data:
Nigeria recorded an estimated 75,000 new HIV infections in 2023.
Approximately 18,000 new infections occurred among people aged 15–24.
An estimated 1.8 million people were living with HIV in 2023.
UNAIDS+1
Young people need accessible, confidential and non-judgmental healthcare services. Prevention programmes must also address misinformation, stigma, limited awareness and barriers to accessing medical facilities.
3. Our Campaign Objectives
Expand HIV prevention awareness among teenagers and young adults.
Support confidential and voluntary HIV testing.
Help eligible HIV-negative individuals access medically supervised PrEP services.
Support access to lenacapavir through authorized healthcare facilities and approved supply channels.
Train healthcare workers and community health educators.
Provide counselling and follow-up services.
Reduce HIV-related stigma and discrimination.
Monitor programme performance and publish transparent funding reports.
4. Estimated Funding Requirement – $250,000
The following is a proposed 12-month programme budget. It is a planning estimate, not a supplier quotation or confirmed drug procurement price.
Budget category | Estimated cost |
Approved HIV prevention services and medical access support | $85,000 |
HIV testing, screening and laboratory services | $35,000 |
Community awareness and educational campaigns | $25,000 |
Healthcare worker training and clinical capacity | $20,000 |
Counselling and participant follow-up | $20,000 |
Outreach, transportation and mobile health services | $25,000 |
Monitoring, evaluation and independent reporting | $15,000 |
Programme administration and safeguarding | $10,000 |
Contingency and emergency programme support | $15,000 |
Total funding required | $250,000 |
5. Who Will Benefit?
The proposed programme will prioritize:
Adolescents and young adults who need accurate HIV prevention information.
Young women and girls facing increased HIV vulnerability.
Young people who may benefit from confidential HIV testing and counselling.
HIV-negative individuals who meet clinical criteria for PrEP.
Underserved communities with limited access to prevention services.
Community health educators and healthcare workers.
The programme will respect privacy, informed consent, safeguarding requirements and applicable Nigerian regulations.
6. Implementation Plan
Period | Activities |
Months 1–2 | Partner selection, needs assessment and programme approvals |
Months 3–4 | Healthcare training and community awareness |
Months 5–8 | Testing, counselling and prevention-service delivery |
Months 9–10 | Continued outreach and participant follow-up |
Months 11–12 | Evaluation, financial reporting and impact assessment |
7. Transparency and Accountability
We understand that donors deserve confidence that their contributions are being used responsibly.
Our proposed accountability commitments include:
Working with recognized Nigerian healthcare providers and authorized partners.
Using documented procurement and expenditure procedures.
Maintaining financial records and supporting receipts.
Protecting participants' medical information.
Publishing periodic progress and financial reports.
Arranging independent financial review or audit.
Reporting programme outcomes without exposing beneficiaries' identities.
Donations will support the programme activities described in this proposal. Any changes to the budget or implementation plan will be documented.
8. Your Donation Can Help Protect Lives
HIV prevention is not only a healthcare responsibility. It is a shared commitment to protecting the future of our communities.
Your contribution can help young people receive accurate information, access confidential testing, consult qualified medical professionals and obtain appropriate prevention services.
Whether you contribute $10, $50, $100 or more, your support can help strengthen HIV prevention efforts in Nigeria.
Together, we can build a healthier, better-informed and more protected generation.
Donate today. Help protect Nigeria's next generation.
How Lenacapavir Can Help
Lenacapavir is a long-acting antiretroviral medicine used for HIV prevention as PrEP in eligible HIV-negative individuals.
Its key benefits include:
Twice-yearly administration: A long-acting option that generally requires injections every six months.
An alternative to daily pills: May help people who find daily oral PrEP difficult.
Medical supervision: Administration requires qualified healthcare professionals.
HIV testing: People must be confirmed HIV-negative before starting and undergo appropriate follow-up testing.
Additional prevention choice: It complements other prevention methods, including condoms, testing, counselling and other approved PrEP options.
Lenacapavir is a long-acting medicine used for HIV prevention (PrEP) in eligible HIV-negative individuals. It is administered twice yearly under medical supervision.
The campaign aims to improve HIV awareness, testing, counselling and access to modern prevention services.
Donations will support medical access, testing, healthcare training, awareness, counselling, outreach and programme monitoring.
The proposed funding target is $250,000 for a 12-month programme.
0 Reviews